NeuroMetrix Reports First Quarter 2014 Financial Results and Business Highlights - Record number of SENSUS devices sold - Launch of second generation SENSUS device - Strong growth in domestic DPNCheck tests - Progress to

Reports First Quarter 2014 Financial Results and

WALTHAM, Mass., April 24, 2014 (BUSINESS WIRE) - NeuroMetrix,

Inc. (the "Company") (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and

point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today reported business

and financial highlights for the quarter ended March 31, 2014.

The Company operates in two primary markets - wearable

medical technology and point-of-care tests. The Company's SENSUS device is a wearable transcutaneous electrical nerve stimulator

indicated for management of chronic pain, and is the only such device cleared by the FDA for use during sleep. It is lightweight

and can be worn during the day while remaining active, and at night while sleeping. SENSUS is beneficial in treating various forms

of chronic pain, particularly neuropathic pain such as painful diabetic neuropathy, which affects about one quarter of people with

diabetes. The Company's point-of-care neuropathy test, DPNCheck, addresses an unmet medical need for accurate and cost-effective

screening, diagnosing and monitoring of peripheral neuropathies such as diabetic peripheral neuropathy. DPNCheck has found growing

acceptance among Medicare Advantage plans where it is used in the clinically and financially important risk adjustment process.

The Company reported recent highlights:

"DJO Global's sales force delivered immediate results

under our new distribution agreement," said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix.

"Their first quarter performance suggests the potential for rapid SENSUS growth. In the point-of-care testing market, Omron

Healthcare is diligently laying the groundwork for DPNCheck in Japan. This is a unique market with a combination of physician reimbursement

for nerve conduction testing and an approved pharmacological agent for treating diabetic peripheral neuropathy. Omron has a strong

presence in the Japan market through complementary products and broad, established distribution."

The Company reported its financial results for Q1 2014. Total

revenues were $1.33 million, slightly below $1.40 million for Q1 2013. Gross profit was 53.8 percent of total revenues compared

to 59.3 percent in Q1 2013. Operating expenses were $2.5 million compared to $3.1 million in Q1 2013. The Company recorded a non-cash

credit of $0.5 million for the revaluation at fair value of outstanding common stock warrants. Net loss was $1.2 million, or $0.21

per share. This compared to a net loss of $2.3 million for Q1 2013, or $1.06 per share. NeuroMetrix reported net cash usage of

$1.6 million and ended the period with cash resources of $7.6 million

Company to Host Live Conference Call and Webcast

NeuroMetrix management will host a conference call today, April

24, 2014 at 8:00 a.m., Eastern time. To access the call in the United States, dial 866-515-2913 and use the confirmation code

40938233. Internationally, the conference call may be accessed by dialing 617-399-5127 and using the same confirmation code. The

call will also be webcast and will be accessible from the Company's website at http://www.neurometrix.com under the "Investor

Relations" tab. A replay of the conference call will be available starting two hours after the call by dialing 888-286-8010,

domestically and 617-801-6888, internationally. The confirmation code to access the replay is 46916035. The replay will be available

for two weeks after the conference call.

NeuroMetrix is an innovative health-care company that develops

wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases,

and sleep disorders. The Company has a major focus on diabetic neuropathies, which affect over 50% of people with diabetes. If

left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual

cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company markets the SENSUS device for

treating chronic pain, focusing on physicians managing patients with neuropathic pain such as painful diabetic neuropathy. The

company also markets DPNCheck, which is a rapid, accurate, and quantitative point-of-care test for peripheral neuropathies such

as diabetic neuropathy. This product is used to detect neuropathies at an early stage and to guide treatment. For more information,

please visit http://www.NeuroMetrix.com.

Safe Harbor Statement

The statements contained in this press release include forward-looking

statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange

Act of 1934, as amended, including, without limitation, statements regarding the company's or management's expectations

relating to the adoption of SENSUS and NC-stat DPNCheck, our ability to build a successful business focused on diabetic and adjacent

neuropathies, our hope of expanding our commercial sales channels for our products and our hope of expanding SENSUS national distribution

to rapidly expand SENSUS awareness and sales. While the company believes the forward-looking statements contained in this press

release are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated

by such forward-looking statements, including, without limitation, our estimates of future performance, and our ability to successfully

develop, receive regulatory clearance or approval, commercialize and achieve market acceptance for any of our products. There can

be no assurance that future developments will be those that the company has anticipated. Such forward-looking statements involve

known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the company's

most recent Annual Report on Form 10-K as well as other documents that may be filed from time to time with the Securities and Exchange

Commission or otherwise made public. The company is providing the information in this press release only as of the date hereof,

and expressly disclaims any intent or obligation to update the information included in this press release or revise any forward-looking

SVP and Chief Financial Officer

Condensed Statements of Operations

Condensed Balance Sheets